🚀 Building a website? Start with reliable WordPress hosting from MilesWeb →
Business news, market intelligence, and global industry analysis.
The Latest

Dr Reddy’s Laboratories to acquire generic injectable products in the US

bypharmanewsdaily
April 19, 2019
Total
0
Shares
0
0
0

Dr Reddy’s Laboratories has agreed to acquire a portfolio of 42 approved, non-marketed abbreviated new drug applications (ANDAs) in the US, which includes more than 30 generic injectable products, from an undisclosed seller.

The generic injectable products would need technology transferred and may be launched within 1-2 years.

According to IQVIA, the value of the total addressable market for the generic injectable products in the US is nearly $645 million for the year 2018.

Erez Israeli – Chief Operating Officer of Dr. Reddy’s Laboratories, said: “The acquisition is in line with our stated strategy to significantly enhance our portfolio in our chosen growth markets. This transaction will help augment our injectables product portfolio in the U.S. market and globally.”

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Eli Lilly's Tirzepatide triumphs in Phase 3 weight loss studies
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Bayer, Orion secures Darolutamide FDA approval for prostate cancer

Darolutamide FDA approval : German pharma giant Bayer and Finnish pharma company Orion have secured approval from the US Food and Drug Administration (FDA) for their non-steroidal androgen receptor inhibitor (ARi) Nubeqa (darolutamide) for the treatment of men having non-metastatic castration-resistant prostate cancer (nmCRPC). The FDA approval of darolutamide was driven on the findings of […]

The post Bayer, Orion secures Darolutamide FDA approval for prostate cancer appeared first on PharmaNewsDaily.com.

bypharmanewsdaily